PMA device
Esprit BTK Everolimus Eluting Resorbable Scaffold System
Abbott Medical · Scaffold, Infrapopliteal, Absorbable (NXW, Class III) · First FDA decision Apr 26, 2024, newest Jul 9, 2026Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
Breakthrough-designated
Device trials
4
Naming "Esprit BTK Everolimus"
MAUDE reports
5
Brand "Esprit BTK Everolimus", since 2015
PubMed studies
0
Mentioning "Esprit BTK Everolimus"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Esprit BTK Everolimus Eluting Resorbable Scaffold System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
P230036-S017 · Decided Jul 9, 2026 · 99 days after receipt · Normal 180 Day Track
Device type: Scaffold, infrapopliteal, absorbable (NXW) · Cardiology
P230036-S013 · Decided Aug 8, 2025 · 29 days after receipt · Normal 180 Day Track No User Fee
Device type: Scaffold, infrapopliteal, absorbable (NXW) · Cardiology
P230036-S010 · Decided Apr 16, 2025 · 27 days after receipt · Normal 180 Day Track No User Fee
Device type: Scaffold, infrapopliteal, absorbable (NXW) · Cardiology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Esprit BTK Everolimus", any status and sponsor, newest update first.
Cardiovascular and Interventional Radiological Society of EuropeAcademic, hospital or other
NCT07270575 · 400 participants (planned) · Start Aug 31, 2026 · Primary completion Aug 2032
Device: Esprit BTK™ Everolimus Eluting Resorbable Scaffold from Abbott · For: Chronic Limb Threatening Ischemia; Chronic Limb-Threatening Ischemia
Sites: Hull, United Kingdom
- Esprit BTK Post-Approval StudyActive, not recruiting
Abbott Medical DevicesPublic (ABT)
NCT06656364 · 200 participants · Start Oct 21, 2024 · Primary completion Apr 30, 2027
Device: Esprit BTK System · For: Chronic Limb-Threatening Ischemia
Sites: Scottsdale, Arizona; Tucson, Arizona; Fresno, California · 39 sites in all
- LIFE-BTK PK Sub-studyActive, not recruiting
Abbott Medical DevicesPublic (ABT)
NCT05208905 · 9 participants · Start Feb 10, 2022 · Primary completion Apr 18, 2023
Device: Esprit BTK Device · For: Critical Limb Ischemia (CLI)
Sites: Jacksonville, Florida; South Dartmouth, Massachusetts; Bartlesville, Oklahoma · 5 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Esprit BTK Everolimus", and for the whole product code for context.
This brand
5 reports: 1 malfunction, 4 injury, 0 death
Whole product code NXW
262 reports: 106 malfunction, 152 injury, 2 death
Newest reports for this brand
2024168-2026-03894 · Received Oct 7, 2026 · Event dated Sep 10, 2026
Device type: Scaffold, Infrapopliteal, Absorbable (NXW)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Pain; Thrombosis/Thrombus
2024168-2026-03819 · Received Oct 2, 2026 · Event dated Sep 10, 2026
Device type: Scaffold, Infrapopliteal, Absorbable (NXW)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Pain; Thrombosis/Thrombus
2024168-2026-03570 · Received Sep 16, 2026 · Event dated Aug 17, 2026
Device type: Scaffold, Infrapopliteal, Absorbable (NXW)
Device problem as coded: Improper or Incorrect Procedure or Method; Ambient Temperature Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Esprit BTK Everolimus"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.